Morquio A Syndrome Clinical Trial
Official title:
A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA
NCT number | NCT01858103 |
Other study ID # | 110-503 |
Secondary ID | |
Status | Approved for marketing |
Phase | N/A |
First received | May 15, 2013 |
Last updated | March 31, 2014 |
Verified date | March 2014 |
Source | BioMarin Pharmaceutical |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Expanded Access |
The Expanded Access Program (EAP) is an open-label, multicenter program to:
1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA)
access to BMN 110 until commercial product is available
2. Collect additional information on the safety and tolerability of BMN 110 administration
in patients with MPS IVA
Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every
week during the program.
Status | Approved for marketing |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Diagnosed with MPS IVA as confirmed by either N-acetylgalactosamine-6-sulfatase (GALNS) enzymatic test (GALNS activity in affected range, beta-galactosidase and a second lysosomal sulfatase activity within normal range) or molecular diagnostic test (two mutations in GALNS identified that have previously been associated with an enzyme defect). - Willing and able to provide written, signed informed consent, or in the case of patients under the age of 18, provide written assent (as required by the IRB) and written informed consent by a legally authorized representative after the nature of the program has been explained, and prior to any program assessments or evaluations. - Sexually active patients must be willing to use an acceptable method of contraception while participating in the program. - Females of childbearing potential must have a negative pregnancy test at Baseline and be willing to have additional pregnancy tests during the program. - Willing and able to comply with all program procedures. Exclusion Criteria: - Pregnant or breastfeeding at Baseline or planning to become pregnant (self or partner) at any time during the program. Patients who become pregnant during the program will be discontinued from the program. - Currently enrolled in an ongoing clinical study of BMN 110. - Discontinued from a BMN 110 clinical study secondary to a safety-related event. - Use of any investigational product (other than BMN 110 in a clinical study) or investigational medical device within 30 days prior to Baseline, or requirement for any investigational agent prior to completion of all scheduled program assessments. - Not a current US resident or expecting to have travel plans outside the US during the planned period of participation in the Expanded Access Program (EAP) that may interfere with dosing regimen, scheduled program visits and safety monitoring. - Any condition that, in the view of the Investigator or sponsor, places the patient at high risk of poor treatment compliance or of not completing the EAP. |
N/A
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
BioMarin Pharmaceutical |
United States, Puerto Rico,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05845749 -
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI
|
Phase 1/Phase 2 | |
Completed |
NCT02294877 -
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
|
||
Completed |
NCT01961518 -
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
|
N/A | |
Completed |
NCT01515956 -
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
|
Phase 2 | |
Recruiting |
NCT05284006 -
Non-invasive Functional Assessment and Pathogenesis of Morquio A
|
||
Completed |
NCT01415427 -
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
|
Phase 3 | |
Recruiting |
NCT04532047 -
In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
|
Phase 1 | |
Completed |
NCT01920828 -
Gait Analysis in MPS IVA
|
||
Terminated |
NCT01697319 -
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
|
Phase 2 | |
Terminated |
NCT01609062 -
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
|
Phase 2 |